Entrada Therapeutics Inc (TRDA)
16.45
+0.68
(+4.31%)
USD |
NASDAQ |
Sep 27, 16:00
16.47
+0.02
(+0.12%)
After-Hours: 20:00
Entrada Therapeutics SG&A Expense (Annual): 32.29M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 32.29M |
| December 31, 2022 | 30.64M |
| December 31, 2021 | 15.20M |
| Date | Value |
|---|---|
| December 31, 2020 | 5.565M |
| December 31, 2019 | 3.608M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
3.608M
Minimum
2019
32.29M
Maximum
2023
17.46M
Average
15.20M
Median
2021
SG&A Expense (Annual) Benchmarks
| Fulcrum Therapeutics Inc | 41.67M |
| Pfizer Inc | 14.77B |
| Sarepta Therapeutics Inc | 481.87M |
| Catalyst Pharmaceuticals Inc | 133.71M |
| Insmed Inc | 344.50M |